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ABSTRACT
Within the last few years, methicillin-resistant Staphylococcus aureus (MRSA) strains encoding Panton-
Valentine leukocidin (PVL) have emerged and spread worldwide. This epidemic can be attributed to a
small number of distinct clones. The present study used a novel assay, based on multiplex linear DNA
ampliﬁcation and subsequent microarray hybridisation, to simultaneously detect all relevant exotoxins,
antimicrobial resistance determinants and the allelic variants of agr. The genes of the staphylococcal
exotoxin-like (set) locus were also included for typing purposes. This assay, together with multilocus
sequence typing (MLST) and spa typing, was applied to 56 clinical isolates and reference strains
representing all major pandemic PVL-MRSA lineages, as well as to phylogenetically-related strains and
putative ancestors. Array hybridisation results allowed the assignment of isolates to clonal groups,
which were in accordance with MLST and spa typing data. Ten distinct clonal groups of PVL-MRSA
(ST1, ST5, ST8, ST22, ST30, ST59 ⁄ 359, ST80 ⁄ 583, ST88, ST93 and ST152), including 12 MLST types, were
identiﬁed and analysed with regard to resistance determinants and genes coding for exotoxins. The
array hybridisation data conﬁrmed that pandemic PVL-positive strains originate from very diverse
genetic backgrounds, and provided insights into the evolution of some lineages. The DNA microarray
technique provides a valuable epidemiological tool for the detailed characterisation of clinical isolates
and comparison of strains at a global level.
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INTRODUCTION
One of the most important clinical pathogens is
Staphylococcus aureus. This bacterium causes
diverse infections, such as wound infections,
abscesses and septicaemia. Some strains can also
cause food poisoning, Ritter’s disease and toxic
shock syndrome (TSS) [1,2]. S. aureus has evolved
to exploit ecological niches created by modern
medicine and intensive care. It frequently infects
intravenous lines and synthetic implants [2], and
expresses a complex system of resistance deter-
minants [3–5] that cause major therapeutic prob-
lems.
Panton-Valentine leukocidin (PVL) is a well-
characterised virulence factor of S. aureus. PVL
is composed of two distinct protein compo-
nents, which together form heptameric pores in
Corresponding author and reprint requests: S. Monecke,
Institute for Medical Microbiology and Hygiene, Faculty of
Medicine Carl Gustav Carus, Technical University of Dresden,
Fetscherstrasse 74, D-01307 Dresden, Germany
E-mail: monecke@rocketmail.com
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases
leukocytes [6], leading to increased virulence.
PVL-positive strains are able to cause chronic or
recurrent skin and soft-tissue infections in immu-
nocompetent individuals [7–11]. Such strains
have also been reported to cause necrotising
pneumonia, with extremely high mortality, either
in previously healthy patients, or as a complica-
tion of viral respiratory tract infection [12–16].
In addition, PVL-positive S. aureus have been
associated with necrotising fasciitis [17], purpura
fulminans [18] and Waterhouse–Friderichsen syn-
drome [19].
PVL was described initially in 1932 [20]. During
the 1950s ⁄ 1960s, the pandemic spread of a PVL-
positive, b-lactamase producing strain (‘phage
type 80 ⁄ 81’) was observed, but this strain receded
after the introduction of penicillinase-resistant
b-lactam agents such as oxacillin [21]. Currently,
global spread of new PVL-positive strains carrying
mecA is occurring, which exhibit resistance to all
b-lactam antibiotics. This development has been
paralleled by the emergence of two new staphylo-
coccal chromosome cassette mec (SCCmec) types
(IV and V), which, in contrast to the ‘older’ SCCmec
types (I–III) found in healthcare-associated meth-
icillin-resistant S. aureus (HA-MRSA), do not affect
the growth rate of the bacteria adversely [22,23].
Strains carrying these older types were restricted
mainly to hospitals, where they had a selective
advantage over susceptible wild-type strains. In
contrast, strains carrying SCCmec types IV and V
have spread outside hospitals as easily as the wild-
type, and are therefore referred to as community-
associated MRSA (CA-MRSA).
Some SCCmec type IV strains also carry the
genes for PVL; such strains were ﬁrst described in
the 1990s [24] and are now distributed world-
wide. They have caused occasional large-scale
outbreaks in communities in which individuals
are in close contact, or share sanitary facilities,
e.g., military units, sports teams or isolated rural
communities [25–29]. Hospital-acquired infec-
tions have also been reported, sometimes reach-
ing epidemic proportions [30]. Furthermore, these
developments have been observed in countries
that do not have major problems with healthcare-
associated MRSA infections, e.g., Denmark [31]
and The Netherlands [32].
It is known that there are distinct epidemic
clones of PVL-positive MRSA, which can be
deﬁned by multilocus sequence typing (MLST)
or spa typing [33,34]. These strains also differ in
resistance to antibiotics other than b-lactams, and
in the presence of virulence determinants other
than PVL [11,35].
The present study established and evaluated a
novel assay for the simultaneous detection of all
relevant exotoxins and antimicrobial resistance
determinants. The technique is based on multi-
plex linear DNA ampliﬁcation and subsequent
diagnostic microarray hybridisation. The assay
was applied to PVL-positive S. aureus isolates
from various countries in order to characterise




Isolates of S. aureuswere cultured on Columbia blood agar and
incubated overnight at 37C. Single colonies were selected and
subcultured. Tests for clumping factor and coagulase were
performed using commercial kits. Antimicrobial susceptibility
tests, including detection of methicillin resistance, were per-
formed according to the standards of the country of origin. The
present study investigated 56 isolates selected because they
had been found to be either PVL-positive or genetically similar
to PVL-positive isolates. The sequenced S. aureus strains MW2,
Sanger MRSA252 and Sanger MSSA476 were also included,
and other sequenced strains (COL, N315, Mu50 and NCTC
8325) were used for array evaluation. Sequenced strains RF122
and USA300 (whose sequences were released during the
course of this study) were not available for testing. Reference
strains ATCC 23925, ATCC 43300 and NARSA247 were
included because of their similarity to study isolates. The
strains included in the study are described in detail in Table S1
(see Supplementary material).
Preparation of genomic DNA
Two inoculation loops of culture material from Columbia
blood agar were suspended in 100 lL of a lysis solution
containing 0.05 mg lysostaphin (Sigma, Steinheim, Germany),
2 mg lysozyme (Sigma), 2 mg ribonuclease A (Sigma), 2 lL
20 mM Tris ⁄HCl pH 8.0, 2 lL 2 mM EDTA and 1 lL Triton X-
100. The suspension was incubated with shaking (300 rpm) for
45 min at 37C, after which 10 lL proteinase K and 100 lL
buffer AL (DNeasy kit; QIAgen, Hilden, Germany) were
added. After a further incubation for 45 min at 56C, the
sample was processed using the QIAgen EZ1 device according
to the manufacturer’s tissue lysis protocol.
Plasmid preparation
Plasmid preparation was performed using buffers P1 to P3
from a Plasmid Midi Kit (QIAgen). Four inoculation loops of
culture material from Columbia blood agar were suspended in
500 lL of buffer P1 containing 0.05 mg lysostaphin, 2 mg
lysozyme and 2 mg ribonuclease A. This suspension was
incubated with shaking (300 rpm) for 45 min at 37C, after
which 500 lL of buffer P2 was added. After incubation for
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10 min at room temperature, 500 lL of ice-cold buffer P3 were
added. The suspension was then cooled on ice for 15 min and
centrifuged (15 000 g) for 35 min at 4C. Two subsequent
phenol-chloroform precipitations were performed. The
remaining aqueous phase was puriﬁed using columns from a
DNaesy Tissue Kit (QIAgen) after being mixed with equal
volumes of buffer AL (DNaesy Tissue Kit) and ethanol.
Plasmid DNA was resuspended in 50 lL distilled water and
visualised by non-denaturing gel electrophoresis. Finally,
bands were cut from the gel and the DNA was resuspended
using a Zymo Gel Recovery kit (HiSS Diagnostics, Freiburg,
Germany). Plasmid preparations were used for microarray-
based genotyping in the same way as genomic DNA.
Microarray design
Table S2 (see Supplementary material) shows the target genes,
sources of the sequence data (accession numbers in GenBank),
and the locations of the probe and primer sequences. Probe
sequences were derived from published sequences using the
Array Design software package (CLONDIAG, Jena, Germany).
All published sequences for speciﬁc targets were used for
sequence alignment. Adjacent consensus regions in the align-
ments of all available sequences of each target were selected
for the design of probes and primers. The resulting oligonu-
cleotide sequences were designed to be speciﬁc for each target,
to be free of self-hybridising sequences, and to have a similar
length, GC content and melting temperature, in order to
provide comparable binding efﬁciency. The nomenclature
used for this study is based on the alignments. For that reason
(for example) enterotoxin ‘seP’ was regarded as synonymous
with seA. Finally, probe and primer sequences were again
analysed against the GenBank database (http://
www.ncbi.nlm.nih.gov/BLAST/) to exclude false-positive
reactions resulting from possible cross-reactivities. Database
entries were also reviewed in order to identify sequence
variations that might result in false-negative reactions. A local
database was established that covered all probe and primer
sequences, as well as all available S. aureus genome sequences.
Match tables were designed using the Array Design Software
Package (CLONDIAG), which listed all theoretically possible
hybridisations of the oligonucleotides to the genomes, allow-
ing up to ﬁve mismatches per oligonucleotide, although
measurable signals can only be produced with up to two
mismatches. This facilitated a prediction of hybridisation
patterns for the sequenced strains. These strains were used
for experimental evaluation, and the prediction was compared
with the hybridisation data obtained.
Microarray-based genotyping
Samples were tested using diagnostic DNA microarrays based
on the ArrayTube platform (CLONDIAG) as described previ-
ously [5,10,36–40]. Probes directed towards species markers,
identiﬁcation of agr types, antibiotic resistance determinants
and exotoxins of S. aureus have been described partially and
evaluated previously [5,10]. Targets are listed in Figs 1–4, and
a complete list of targets and probes is shown in Table S2 (see
Supplementary material).
The protocol used for ampliﬁcation and labelling of target
DNA is based on a linear PCR-like approach that uses only
one primer per target (site-speciﬁc ampliﬁcation and label-
ling), thereby facilitating an extremely high degree of
multiplexing, in which 128 primers were used simulta-
neously (Table S2). The ampliﬁcation protocol has been
described previously [5].
For at least one representative strain from every clonal
group, an alternative protocol for random-primed genome
labelling was used [10,37,38]. In brief, arbitrary extension
products were generated from genomic DNA in a sequen-
ase-driven primer extension using primers consisting of a
randomised octamer and a conserved sequence. In a second
round, the extension products were re-ampliﬁed using a
PCR with a biotinylated primer targeting the conserved
sequence. The resulting amplicons were used for hybridisa-
tion.
Hybridisation procedures were identical for both approa-
ches and have been described previously [5]. After staining for
10–30 min with horseradish-peroxidase-based tetramethyl-
benzidine precipitation staining, the resulting pattern was
recorded and analysed using an ATR01 reader (CLONDIAG)
and IconoClust software (CLONDIAG) according to the
manufacturer’s instructions. The signal intensity and local
background of each spot (i.e., probe position) on the array
were measured by transmission. For the interpretation of raw
data, the normalised intensity (NI) was ﬁrst calculated, in
which NI = 1 – (M ⁄BG), where M is the average intensity of a
spot, and BG is the intensity of the local background, giving
results between 0 (weak signal ⁄negative) and 1.0 (strong
signal ⁄positive). The average values for control spots and
species markers (ribosomal probes, femA, gapA, katA, coa, spa,
sak and sbi) were calculated and used for assessing the test
validity and for deﬁning breakpoint values. If this average
value was below a predeﬁned threshold (0.4), the test was
regarded as invalid. If the normalised intensity for a given
probe was < 33% of the average value of the control spots and
species markers, the corresponding target was regarded as
absent ⁄negative.
An exception concerned the probes for the set1, set4 and
SACOL1180 ⁄ SAR1141 genes. These genes each have two or
three allelic variants, which differ only by single nucleotide
polymorphisms. For these targets, the probe with the strongest
signal was regarded as positive, while the probes that yielded
weaker signals were considered to be negative, regardless of
their actual normalised intensities. For set6, four probes
recognising two distinct binding sites were designed (Table
S2), and determination of a set6 allele resulted from the
combination of positive results.
Typing methods
The isolates were also typed using several different approaches.
agr groups are based on a signalling pathway involving
auto-inducing peptides. Peptides produced by some strains
inhibit the expression of agr in other strains, resulting in
bacterial interference and exclusion of the other strains. This
incompatibility has resulted in the formation of four mutually
inhibitory groups that are associated loosely with clinical
disease [41,42]. The agr groups were determined by microarray
hybridisation using the probes listed in Table S2.
spa typing, i.e., typing based on sequence polymorphisms of
repeating units within the staphylococcal protein A gene (spa),
was performed as described previously [33]. Types were
assigned using the Ridom SpaServer database (http://
www.spa.ridom.de) and SPA Type Mapper software (http://
www.clondiag.com/technologies/download.php?ﬁle=spa).
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Multilocus sequence typing (MLST), a sequence-based
approach targeting polymorphisms among several housekeep-
ing genes, was performed as described by Enright et al. [34].
PCR products were puriﬁed using a PCR Puriﬁcation Kit
(QIAgen) and both strands were sequenced on the CEQ 8000
Genetic Analysis System (Beckman Coulter, High Wycombe,
UK). BioNumerics software (Applied Maths, St-Martens-
Latem, Belgium) was used to align and analyse the sequences.
Allelic proﬁles and sequence type (ST) designations were
assigned using the MLST database (http://www.mlst.net).




Experimental procedures and data processing
were evaluated by performing array experiments,
using both labelling and ampliﬁcation proce-
dures, on DNA samples from S. aureus strains
sequenced previously, i.e., MW2, Mu50, N315,
MRSA 252, MSSA 476, NCTC 8325 and COL. The
hybridisation patterns for these strains were in
full agreement with the published data [44–47]
and the match tables described above. For targets
that were not present in these strains, e.g., etA, etB
and edinC, other reference strains (CIP107093,
NARSA266) were used as controls (for additional
strains, see [5]). Results for the strains MRSA252,
MSSA476 and MW2 are shown in Figs 1–4. For
targets of high clinical signiﬁcance (i.e., genes
encoding antibiotic resistance genes, PVL, toxic
shock syndrome toxin, enterotoxins A, B and C,
and exfoliative toxins A and B), PCR products
were generated from a reference strain that
included both probe and primer-binding sites of
the array-based assay. Amplicons were cloned
into plasmids and used in microarray experi-
Fig. 1. Antibiotic resistance genes in the strains studied. Panton-Valentine leukocidin (PVL)-positive strains are indicated
in bold letters. Black boxes, positive; white boxes, negative; divided boxes, divergent results using the two labelling
approaches; shaded boxes, variable.
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ments instead of genomic DNA, using an indi-
vidual array for each individual target [5]. As
each of these amplicons hybridised only with the
corresponding probe on the array, cross-reactiv-
ities were ruled out experimentally.
Array hybridisation results
Thirty-nine PVL-positive isolates of S. aureus were
tested. A further 17 strains were included for
comparison because their hybridisation patterns
and ⁄ or MLST and spa types suggested phylo-
genetic relationships to PVL-positive strains.
Strain characteristics and typing results are listed
in Table S1. Hybridisation patterns were charac-
teristic for clonal groups as deﬁned by MLST.
Complete array hybridisation data are presented
in Figs 1–4, which show, respectively, the distri-
bution of antibiotic resistance genes, superanti-
genic toxins, leukocidins and other virulence
factors, as well as set genes. Brief descriptions of
the different clonal groups (listed by agr group
and MLST type) are given below.
agr group I, ST8
Array hybridisation data for ST8 clinical isolates
were generally in agreement with the published
sequence of strain USA300 (GenBank NC_007793
[48]), although these isolates were obtained from
geographically diverse locations. All isolates car-
ried lukS ⁄ F-PVL, mecA and blaZ, enterotoxin
genes seK and seQ and the ubiquitous enterotoxin
homologue (GenBank entries SAUSA300–1559,
Fig. 2. Genes for superantigenic toxins in the strains studied. Panton-Valentine leukocidin (PVL)-positive strains are
indicated in bold letters. Black boxes, positive; white boxes, negative; divided boxes, divergent results using the two
labelling approaches.
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SAV1601, SA1429, MW1552, SAR1679, SAS1538
and SACOL1657). Genes seQ and set21 were
detectable only by random-primed genome label-
ling, which is consistent with the genome se-
quence data showing divergent sequences within
the primer-binding sites of these genes. The
isolates also harboured the lukD ⁄E and hlg genes
(lukS ⁄ F, hlgA). The b-haemolysin gene was trun-
cated, as shown by positive results with the
random-primed genome labelling and negative
results with site-speciﬁc ampliﬁcation and label-
ling, as the primer and probe were designed to
produce no signal in case of a phage insertion into
hlb (see Discussion). While chromosomal genes
were conserved among the isolates and the
sequenced strain USA300, the plasmid content
proved to be highly variable. Plasmid prepara-
tions of all the ST8 isolates tested yielded several
plasmids. Resistance genes ermC and tetK were
shown to be plasmid-borne, but some plasmids
carried genes that were not represented on the
array.
The ST8-MRSA II strain (also known as Irish-1
EMRSA) appeared to be related to this PVL-
negative MRSA, but differed in spa type, SCCmec
type (an aadD-negative variant of SCCmecII),
absence of PVL, and in harbouring seA instead
of seK and seQ.
agr group I, ST22
Two PVL-positive isolates, one outbreak isolate
from Bavaria and one from the UK, were ana-
lysed. The Bavarian isolate contained mecA and
Fig. 3. Genes for leukocidins, haemolysins and other virulence factors in the strains studied. Panton-Valentine leukocidin
(PVL)-positive strains are indicated in bold letters. Black boxes, positive; white boxes, negative; divided boxes, divergent
results using the two labelling approaches; shaded boxes, variable.
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blaZ, and the UK isolate contained mecA, aacA-
aphD, aadD and dfrA. In both isolates, enterotoxin
genes seG, seI, seM, seN, seO, seU ⁄ seY, as well as
the ubiquitous enterotoxin homologue, were
found. The isolates were positive for the lukS ⁄ F-
PVL genes, but the hlg genes and lukD ⁄E were not
present. Haemolysin genes hla and hld were
detected. set carriage was remarkable as isolates
from this group showed a strong cross-reactivity
between set3 and SAR0427, as well as between
set7 and SAR0423, which was not observed in any
isolates from the other groups.
These isolates showed great similarity to
EMRSA-15 (two isolates from Germany (the
Barnim epidemic strain) and two from the UK),
which differed in being lukS ⁄ F-PVL-negative, but
which were usually ermC-positive.
agr group I, ST59 ⁄ 359
Two isolates were tested. One isolate from Aus-
tralia was MLST type 59 and spa type t437, while
the other (from the UK) belonged to MLST type
359 (a single locus variant of ST59) and spa type
Fig. 4. Staphylococcal exotoxin-like (set) genes in the strains studied. Panton-Valentine leukocidin (PVL)-positive strains
are indicated in bold letters. Black boxes, positive; white boxes, negative; divided boxes, divergent results using the two
labelling approaches; shaded boxes, variable. The set genes are listed in the succession in which they occur in the
sequenced strains (for nomenclature and deﬁnitions of allelic variants, see Table S2).
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t316. Both harboured mecA, but differed with
regard to other resistance genes. The Australian
ST59 isolate contained blaZ, aphA3, sat and tetK.
Both isolates were positive for seB, seK, seQ and
the ubiquitous enterotoxin homologue; they con-
tained lukS ⁄ F-PVL and the hlg genes, but not
lukD ⁄E. The b-haemolysin gene was intact (i.e.,
detectable by site-speciﬁc ampliﬁcation and label-
ling), and sak (staphylokinase gene) was not
present.
agr group I, ST152
The description of this unusual type belonging to
agr group I, MLST type 152 and spa type t355 was
based on an isolate obtained from an immigrant
child fromMacedonia. It was positive formecA and
blaZ, andharboured the gentamicin resistance gene
aacA-aphD, which is rare among CA-MRSA. It
contained the ubiquitous enterotoxin homologue,
but none of the other enterotoxin genes. It was
positive for lukS ⁄ F-PVL; lukD ⁄Ewas not detectable
by site-speciﬁc ampliﬁcation and labelling, butwas
detected using the random-primed genome label-
ling approach. Faint signals were obtained for lukF
and hlgA using the former approach, but bothwere
clearly positive using the latter approach. This
might indicate a deviant sequence. This isolate was
the only one tested that contained both an untrun-
catedhlbgene and sak.The edinBgenewasdetected,
but etD (exfoliative toxin D) was absent. This
contrasts with other isolates (ST80) in which these
genes occurred together.
agr group II, ST5
One ST5 spa type t002 isolate from the UK was
remarkable for being the only lukS ⁄ F-PVL-posit-
ive agr group II isolate found. It carried mecA, blaZ
and several enterotoxin genes (variant seA, seD,
seG, seI, seJ, seM, seN, seO, seR, seU, seY and the
enterotoxin homologue). Furthermore, it har-
boured hlg genes and lukD ⁄E. The b-haemolysin
gene hlb seemed to be truncated and sak was
present.
Related lukS ⁄ F-PVL-negative specimens inclu-
ded a SCCmecIV, spa type t548 isolate (the
‘paediatric MRSA clone’) and two spa type t003
isolates belonging to the Rhine-Hessen epidemic
strain (ST225). The latter also differed in being
ermA- and aadD-positive. This was consistent with
the presence of a SCCmecII element [43].
agr group III, ST1
The ST1 clonal group included the archetypal CA-
MRSA strain MW2 (GenBank NC_003923) and the
PVL-negative MSSA476 (GenBank NC_002953),
both of which have been fully sequenced. Array-
based data for strains MW2 and MSSA476 were in
full agreement with the genome sequences pub-
lished previously. Essentially, these strains were
identical, except for the presence of mecA, entero-
toxin genes seC and seL, and lukS ⁄F-PVL in MW2.
Two PVL-positive clinical MRSA isolates (from
Australia and the UK) and one PVL-positive
mecA-negative isolate (from Germany) were as-
signed to ST1. Two related, but lukS ⁄F-PVL-
negative, MRSA isolates (from Germany and the
UK) were also included. All isolates were highly
similar to each other and to the sequenced strains.
The carriage of set genes was identical to MW2
and MSSA476. Variability occurred with respect
to the presence of PVL, enterotoxin genes seC and
seL (see above) and resistance determinants. The
PVL-positive mecA-negative MSSA from Ger-
many contained blaZ, aphA and sat. One PVL-
negative MRSA from the UK contained a
plasmid-borne ermC gene, and the lukS ⁄F-PVL-
positive isolate from the UK harboured tetK.
agr group III, ST30 ⁄ 36
The analysis of the ST30 clonal group (‘South-
west Paciﬁc clone’ or WSPP, ‘West Samoan Phage
Pattern’) was based on four isolates, two from
Switzerland, one from the UK, and one from
Australia. For comparison, putative mecA-negat-
ive precursors of this strain, namely ATCC 25923
(Seattle, USA, 1945) and phage group 80 ⁄ 81
isolates (from the UK, 1955, and from Australia,
late 1960s) were included. Additionally, a mecA-
negative isolate (from a patient with long-stand-
ing furunculosis), which was unique in carrying
both lukS ⁄ F-PVL and tst1, belonged to this group
(not shown in Figs 1–4). ATCC 25923 and the
latter isolate harboured neither blaZ nor mecA, the
phage group 80 ⁄ 81 isolates were positive for blaZ,
and all ‘South-west Paciﬁc clone’ MRSA isolates
carried both mecA and blaZ. Enterotoxin genes
seG, seI, seM, seN, seO, seU ⁄ seY and the ubiquitous
enterotoxin homologue, as well as lukS ⁄ F-PVL
and the hlg genes, were detected in all isolates. In
contrast to the other isolates, ATCC 25923 did not
contain sak, and its hlb locus was intact.
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All strains in this group carried a unique
complex of set genes, which is represented in
sequenced strain MRSA252 (SAR0422-025,
SAR027-029, SAR031, SAR035 and SAR1139-
1141), and which sets ST30 ⁄ 36 clearly apart from
other lineages (Fig. 4).
Two clinical isolates of EMRSA-16, MRSA252
and ATCC 43300, as well as NARSA247, were
found to be related and produced similar hybrid-
isation patterns, especially with regard to set
genes. These strains were lukS ⁄F-PVL-negative.
The tst1 gene was found in NARSA247, the two
clinical EMRSA-16 isolates and ATCC 43300, but
not in MRSA252. Other differences included the
carriage of resistance genes (mecA, blaZ, aadD,
acaA-aphD, ermA, mupR, dfrA) and enterotoxin
genes (Figs 1 and 2).
agr group III, ST80
The ST80 clonal group has previously been
described in detail, based on outbreak isolates
from Germany [10,49]. Additional isolates from
Australia (WA-MRSA-17), the UK and Switzer-
land were tested in the present study. ST80
isolates belonged to agr group III, MLST type 80
or 583 (a single locus variant of ST80 [50]), and spa
types t044, t131 or t416. All contained mecA, aphA3
and sat, and most isolates contained the plasmid-
borne blaZ, tetK and far1 genes [10]. Two isolates
carried linA on a second plasmid. ST80 isolates
were invariably positive for lukD ⁄E, lukS ⁄ F-PVL,
edinB and etD. Interestingly, isolates from this
group did not harbour any enterotoxin genes,
except for the ubiquitous enterotoxin homologue.
The carriage of set genes was similar to MW2 and
MSSA476. Differences included a mutation ⁄dele-
tion in set6 (one of two probes gave a signal) and
the absence of set21.
agr group III, ST88
This description is based on one isolate, from a
patient with a history of travel from Bangladesh
to the UK, which belonged to agr group III, MLST
type 88 and spa type 690. Based on an analysis of
set genes (Fig. 4) and spa typing, this isolate was
related to ST1 and ST80; spa type t690 has the
repeat sequence 07-12-21-17-13-13-34-34-34–33–
34, while the other two clones usually have spa
type t044 (07-23-12-34-34-33–34), t127 (07-23-21-
16-34-33–13) or t131 (07-23-12-34-33-34). The
resistance genes mecA, blaZ and tetK were detec-
ted, as well as lukS ⁄ F-PVL, hlg genes and lukD ⁄E,
but this isolate did not contain sak. There was a
positive signal for hlb when using the site-speciﬁc
ampliﬁcation and labelling approach, indicating
that this gene was intact.
agr group III, ST93
One isolate of ST93 (also known as ‘WA-MRSA-7’
or ‘Queensland Clone’) was tested and found to
be positive for mecA and blaZ. This isolate did not
harbour tst1 or any enterotoxin genes, including
the ubiquitous enterotoxin homologue. The c-
haemolysin genes were absent; lukS ⁄ F-PVL was
detected, and haemolysins a, d and III were
present. The isolate was unique in carrying splA
but not splB. The leukocidin genes lukD and lukE
were detectable by random-primed genome label-
ling, but only lukD was detected using site-
speciﬁc labelling. The carriage of set genes by this
strain was distinctive, and it was observed that
several of these genes were detectable only by
random-primed genome labelling (Fig. 4).
DISCUSSION
Clinical isolates of S. aureus from Australia,
Germany, Switzerland and the UK, as well as
reference strains, were analysed using a novel
DNA microarray approach. To the best of our
knowledge, the array covered all relevant exotox-
in genes and antimicrobial resistance determi-
nants. There was a good correlation with
established typing methods, resulting in rather
uniform hybridisation patterns for isolates that
belonged to a given spa or MLST type. This
ﬁnding is remarkable, as the strategies used for
typing were completely different. MLST and spa
typing are based on random changes in one or
several ubiquitous genes. Assuming that the
environmental pressure on these mutations is
limited, analysis was thought to reveal phylo-
genetic relationships. In the microarray-based
approach, a comparatively high number of targets
(144 genes or distinct allelic variants thereof) were
monitored; these are likely to be subject to high
selective pressure as they are involved in antibi-
otic resistance or interactions with the host, with
many being encoded on mobile genetic elements.
None of these genes is speciﬁc for a clone, but
parallel analysis of a high number of genes
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resulted in a stable lineage proﬁle that was
generally in agreement with MLST and spa typing
data. Occasional minor differences were ob-
served; thus, the array was not able to discrim-
inate between ST80 and ST583, with the latter
being a single locus variant of ST80 [50], or
between spa types t44 and t416, which both belong
to ST80. Nevertheless, the array provided com-
prehensive strain characterisation within a single
experiment, including data concerning antimicro-
bial resistance and toxin gene carriage, thereby
allowing an assessment of virulence.
At a practical level, the DNA microarray
technique provided more clinically useful infor-
mation than (e.g.) MLST, which fails to differ-
entiate between coexisting PVL-positive and
PVL-negative ST22 strains, or between oxacillin-
susceptible and oxacillin-resistant ST1 isolates.
The DNA microarray had a high speed and
throughput, and proved to be a powerful tool
for inter-strain analyses in order to facilitate
epidemiological monitoring and assignment of
clinical isolates to epidemic strains. In general, the
random-primed genome labelling approach was
suitable for detecting truncated genes or un-
known allelic variants, because it required only
the presence of a relatively conserved probe-
binding site. For site-speciﬁc ampliﬁcation and
labelling, the adjacent presence of two binding
sites (for probe and primer) was needed. This
resulted in higher speciﬁcity, but deletions or
divergent sequences affecting the primer binding
site (e.g., entQ and set21 in ST8), as well as large
insertions between the binding sites (see below),
caused negative results. Therefore, unknown or
aberrant strains should be examined using ran-
dom-primed genome labelling, but site-speciﬁc
ampliﬁcation and labelling is more suited for
routine tasks. This protocol required c. 1.5 h for
DNA preparation, 2–3 h for ampliﬁcation (site-
speciﬁc labelling), and 3 h for hybridisation,
staining and analysis, enabling one technician to
test up to 20 isolates a day.
Data from this study, as well as results pub-
lished previously [30,35,51], show that completely
unrelated strains from different agr groups may
evolve into epidemic MRSA clones. The diversity
of genetic backgrounds and the detection of PVL-
negative, but otherwise related, strains indicated
frequent and independent acquisition of lukS ⁄
F-PVL by S. aureus. This is in agreement with
sequence data and observations showing that
lukS ⁄ F-PVL is carried and transmitted by phages
[52–54]. In evolutionary terms, these phages
represent a transition from parasitism to cooper-
ation, as they cause no harm to their host, and
actually enhance its ﬁtness. However, without
testing a large number of chronological isolates, it
is not possible to determine whether a strain
started to spread following acquisition of PVL, or
whether an already widespread strain had a
higher probability of being transformed, simply
by being more common and more likely to
encounter a PVL-carrying phage. The ﬁrst possi-
bility could have occurred with the European
ST80 clone, which has spread throughout Europe
and the Middle East [10,35,51,55] after it was ﬁrst
observed in 1993 in Denmark [56] and 1998 in
Greece [57], but for which no PVL-negative
relatives or putative ancestors have yet been
identiﬁed. The second alternative is more likely
for ST5 and ST22. The PVL-negative ST5 (‘paedi-
atric clone’) and ST22 (EMRSA-15 ⁄ ¢Barnim epi-
demic strain¢) clones were already widespread
and common for many years before outbreaks
caused by PVL-positive descendants were ﬁrst
observed (ST5 in Slovenia [28] and ST22 in
Bavaria [30]).
The sak staphylokinase gene is also a phage-
borne virulence factor, and is transferred by
bacteriophages that integrate into hlb [58]. This
explains the divergent results of the two different
ampliﬁcation and labelling approaches for hlb in
most strains. In the random-primed genome
labelling approach, hlb was always detected
because the phage does not affect the probe-
binding site. With site-speciﬁc ampliﬁcation, the
phage integration renders hlb undetectable by
increasing the distance between primer and probe
binding sites from 17 or 18 bp to nearly 43 000 bp
(phage phi13 provirus genome, GenBank
NC_004617 [58]). Strains that carry the phage do
not produce b-haemolysin; thus, it is impossible
to perform a CAMP test [59] with Streptococcus
agalactiae. The majority of study isolates contained
sak and truncated hlb. The ST152 isolate was
unique as it carried sak and an intact hlb. Some
isolates (from ST22, ST59 ⁄ 359 and ST88; Fig. 3), as
well as the ancient strain ATCC 25923, harboured
an intact hlb, but not sak.
This comparative analysis of a large number of
S. aureus isolates showed that mobile genetic
elements and horizontal gene transfer are of great
clinical importance. For instance, resistance deter-
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minants are commonly situated on transposons
(aphA3 plus sat [60]) or plasmids [10,48,61]. Using
the DNA microarray, it was possible to compare
related isolates in order to identify variable
features. Plasmid preparations were then ob-
tained from isolates with such traits, ampliﬁed
and hybridised. This experimental approach
proved to be very efﬁcient for the detection of
plasmids, including plasmids coding for ermC,
tetK, far1, blaZ and linA in the study strains. Many
virulence factors were found to occur in clusters
corresponding to so-called pathogenicity islands
(seD plus seJ plus seR; etD plus edinB; tst1 plus seC
plus seL). These clusters were observed in unre-
lated strains, which is consistent with their loca-
tion on mobile genetic elements. Large, multigene
clusters even occurred in unrelated S. aureus
strains belonging to different agr groups. Thus,
the egc cluster (seG, seI, seM, seN, seO, seU ⁄ seY)
was detected in agr group I (ST22), agr group II
(ST5) and agr group III (ST30 ⁄ 36). In contrast,
strains belonging to a single agr group might
carry different multigene clusters, and (e.g.) sev-
eral different set clusters were found in agr group
III strains (Fig. 4). The occurrence of a set or
enterotoxin gene cluster within different agr
groups, and the presence of different clusters
within a single agr group, could indicate occa-
sional replacements of rather large portions of the
chromosome. Thus, Robinson and Enright [62]
suggested that ST239 was a mosaic form derived
from ST8 and ST30.
The different forms of inter-strain transfer of
genetic elements facilitate evolutionary changes
resulting in the emergence and spread of more
successful and ⁄ or virulent strains, e.g., those
associated with the epidemic of TSS in the
1970s ⁄ 1980s, or recurrent pandemics of PVL-
positive S. aureus. The evolution of the especially
successful clonal group ST30 ⁄ 36, which comprises
the ancient clone 80 ⁄ 81, the majority of TSS
isolates, the ‘South-west Paciﬁc PVL-MRSA’, and
the widespread EMRSA-16, has been described
previously [21]. ATCC 25923, which was found
recently to be PVL-positive [63], belongs, accord-
ing to the present hybridisation data, to the same
group. As this strain was isolated in 1945, the
evolution of the ST30 ⁄ 36 lineage can be traced
back for 60 years. Compared with ATCC 25923,
phage group 80 ⁄ 81 isolates from the 1950 ⁄ 1960s
acquired b-lactamase and a sak-carrying phage.
After a further 30 years, the ‘South-west Paciﬁc
clone’ emerged following acquisition of a SCC
mecIV element. The ST30 ⁄ 36 lineage also includes
EMRSA-16 and NARSA247 (as a representative
for TSS strains), which were highly similar with
respect to most markers, including the MRSA252-
like alleles of set genes. The evolution of this
clonal group is especially interesting as it includes
multiple independent acquisitions of mecA. Thus,
the HA EMRSA-16 strain harbours SCCmec type
II, while the CA ‘South-west Paciﬁc clone’ con-
tains SCCmecIV. Evidence was also found for
parallel developments in ST5 and ST8. A PVL-
positive ST5 isolate and a related PVL-negative
epidemic strain (‘paediatric clone’) differed from
another strain (ST5 ⁄ ST225-MRSA II, ‘Rhine-Hes-
sen epidemic strain’, or EMRSA-3) in having
SCCmecIV. ST8-MRSA may harbour SCCmecII
(‘Irish 1’ strain) while others contain an SCCmecIV
element as well as PVL (‘USA300’ and ST8-MRSA
study isolates).
Several isolates of ST1 were characterised that
represent different steps in the evolution of this
lineage. MSSA476 could be regarded as the
lukS ⁄ F-PVL-negative, methicillin-susceptible pre-
cursor of this clonal line (Table S1; Figs 1 and 3).
Two of the isolates described above had acquired
mecA, but not lukS ⁄F-PVL. Another isolate was
positive for lukS ⁄ F-PVL, but not for mecA. Given
that MW2 and two isolates eventually contained
lukS ⁄ F-PVL and mecA, the evolution of this clonal
line probably involved multiple acquisitions
and ⁄ or deletions of these genes. Two other types,
ST80 and ST88, appeared to be related to ST1
because of similar or identical spa types, and a
similarly structured set locus. Whether these
lineages diverged before or after acquiring PVL
and ⁄ or mecA cannot be determined as no ‘missing
links’ have been identiﬁed to date.
ST88 and ST152 represent distinctive strains
from patients with a history of travel (Bangladesh
and Macedonia, respectively). ST152 has been
found recently in Slovenia [28], which together
with the Macedonian background of the study
isolate might indicate a distribution in the
Balkans. There are currently no detailed data
concerning the distribution or phylogenetic back-
ground of these strains, although strains related
to ST152 have been described in western Europe
and Australia [64]. It is possible that these and
other, as yet undescribed, clones of PVL-MRSA
evolve and circulate largely unmonitored. The
well-known ST1, ST8, ST30 and ST80 strains are
246 Clinical Microbiology and Infection, Volume 13 Number 3, March 2007
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 13, 236–249
prevalent in regions where there are laboratories
collecting and characterising PVL-MRSA (mainly
Australia, Japan, western Europe and North
America). Even within these regions, it is likely
that a high proportion of PVL-MRSA infections
remains undiagnosed [10], and the evolution of
S. aureus outside these regions is largely unmoni-
tored. Given the high plasticity of the S. aureus
genome, its multitude of resistance and virulence
factors, and the relatively high frequency of gene
transfers, it is highly probable that further emer-
gence and spread of new epidemic strains will
occur. For this reason, continued surveillance is
imperative to elucidate the global epidemiology
of these strains and to guide effective therapeutic
and control strategies.
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